BR112019025866A2 - compostos e composições para indução de condrogênese - Google Patents

compostos e composições para indução de condrogênese Download PDF

Info

Publication number
BR112019025866A2
BR112019025866A2 BR112019025866-3A BR112019025866A BR112019025866A2 BR 112019025866 A2 BR112019025866 A2 BR 112019025866A2 BR 112019025866 A BR112019025866 A BR 112019025866A BR 112019025866 A2 BR112019025866 A2 BR 112019025866A2
Authority
BR
Brazil
Prior art keywords
substituted
carboxamide
oxabicyclo
compound
methyl
Prior art date
Application number
BR112019025866-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Ha-Soon Choi
Jiqing Jiang
James Paul LAJINESS
Bao Nguyen
Hank Michael James Petrassi
Zhicheng Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112019025866A2 publication Critical patent/BR112019025866A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112019025866-3A 2017-06-09 2018-06-07 compostos e composições para indução de condrogênese BR112019025866A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762517394P 2017-06-09 2017-06-09
US62/517,394 2017-06-09
PCT/IB2018/054123 WO2018225009A1 (en) 2017-06-09 2018-06-07 Compounds and compositions for inducing chondrogenesis

Publications (1)

Publication Number Publication Date
BR112019025866A2 true BR112019025866A2 (pt) 2020-07-14

Family

ID=62837959

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019025866-3A BR112019025866A2 (pt) 2017-06-09 2018-06-07 compostos e composições para indução de condrogênese

Country Status (37)

Country Link
US (3) US11091499B2 (cg-RX-API-DMAC7.html)
EP (3) EP3634967A1 (cg-RX-API-DMAC7.html)
JP (2) JP7229945B2 (cg-RX-API-DMAC7.html)
KR (1) KR102656524B1 (cg-RX-API-DMAC7.html)
CN (1) CN110719913B (cg-RX-API-DMAC7.html)
AR (1) AR113227A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018279306C1 (cg-RX-API-DMAC7.html)
BR (1) BR112019025866A2 (cg-RX-API-DMAC7.html)
CL (1) CL2019003564A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019013706A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190551A (cg-RX-API-DMAC7.html)
CU (1) CU24577B1 (cg-RX-API-DMAC7.html)
DK (1) DK3915994T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2019000305A (cg-RX-API-DMAC7.html)
EA (1) EA201992858A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19086712A (cg-RX-API-DMAC7.html)
ES (1) ES2971319T3 (cg-RX-API-DMAC7.html)
FI (1) FI3915994T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240155T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065194T2 (cg-RX-API-DMAC7.html)
IL (2) IL300755A (cg-RX-API-DMAC7.html)
JO (1) JOP20190282B1 (cg-RX-API-DMAC7.html)
LT (1) LT3915994T (cg-RX-API-DMAC7.html)
MA (2) MA50547A (cg-RX-API-DMAC7.html)
MX (1) MX389169B (cg-RX-API-DMAC7.html)
MY (1) MY198288A (cg-RX-API-DMAC7.html)
PE (1) PE20200403A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502764A1 (cg-RX-API-DMAC7.html)
PL (1) PL3915994T3 (cg-RX-API-DMAC7.html)
PT (1) PT3915994T (cg-RX-API-DMAC7.html)
RS (1) RS65161B1 (cg-RX-API-DMAC7.html)
SA (1) SA519410729B1 (cg-RX-API-DMAC7.html)
SI (1) SI3915994T1 (cg-RX-API-DMAC7.html)
TW (1) TWI782036B (cg-RX-API-DMAC7.html)
UY (1) UY37759A (cg-RX-API-DMAC7.html)
WO (1) WO2018225009A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201907358B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37759A (es) * 2017-06-09 2019-01-31 Novartis Ag Compuestos y composiciones para inducir condrogénesis
ES2963508T3 (es) * 2018-12-06 2024-03-27 Novartis Ag Derivados de 5-hidroxi-7-oxabiciclo[2.2.1]heptano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular
WO2020115684A1 (en) * 2018-12-06 2020-06-11 Novartis Ag 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
ECSP982358A (es) 1998-01-06 1998-12-22 Derivados ciclicos de sulfona
US6407250B1 (en) * 2000-09-14 2002-06-18 Allergan Sales, Inc. Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
US6369089B1 (en) 2000-09-14 2002-04-09 Allergan Sales, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
CN1213050C (zh) 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物,其制备方法和作为农药的用途
US6653468B1 (en) 2002-07-31 2003-11-25 Isis Pharmaceuticals, Inc. Universal support media for synthesis of oligomeric compounds
JP2005068052A (ja) 2003-08-22 2005-03-17 Mitsui Chemicals Inc 新規なフラン誘導体及びその製造方法
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
US7595327B2 (en) * 2005-03-21 2009-09-29 Wyeth Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
US9233106B2 (en) 2006-07-12 2016-01-12 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
WO2010114997A1 (en) 2009-04-02 2010-10-07 Allergan, Inc. Prostaglandin e receptor antagonists
PE20160507A1 (es) 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
CN101628951B (zh) 2009-08-12 2011-06-22 中国石油天然气股份有限公司 烯烃聚合用固体催化组分及其催化剂
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012177856A2 (en) 2011-06-21 2012-12-27 Adispell, Inc. Cognition modification
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
EP2968330B1 (en) * 2013-03-15 2021-09-29 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
HRP20241236T1 (hr) * 2014-05-13 2024-12-06 Novartis Ag Spojevi i pripravci za induciranje hondrogeneze
JP2016204316A (ja) 2015-04-24 2016-12-08 日東電工株式会社 核酸固相合成用リンカー及び担体
UY37759A (es) 2017-06-09 2019-01-31 Novartis Ag Compuestos y composiciones para inducir condrogénesis

Also Published As

Publication number Publication date
EP4299123A2 (en) 2024-01-03
EP4299123A3 (en) 2024-04-03
TW201902900A (zh) 2019-01-16
MX389169B (es) 2025-03-20
JOP20190282B1 (ar) 2024-04-18
IL300755A (en) 2023-04-01
CN110719913A (zh) 2020-01-21
JP7432778B2 (ja) 2024-02-16
NZ759434A (en) 2024-01-26
CO2019013706A2 (es) 2020-04-01
RU2019144107A3 (cg-RX-API-DMAC7.html) 2021-07-30
PH12019502764A1 (en) 2020-07-13
AU2018279306A1 (en) 2019-12-05
US20210079010A1 (en) 2021-03-18
HRP20240155T1 (hr) 2024-04-12
CN110719913B (zh) 2022-10-28
PE20200403A1 (es) 2020-02-26
CU24577B1 (es) 2022-02-04
EP3634967A1 (en) 2020-04-15
MA50547A (fr) 2020-09-16
CR20190551A (es) 2020-01-28
KR102656524B1 (ko) 2024-04-12
FI3915994T3 (fi) 2024-02-14
MA57022B1 (fr) 2024-02-29
IL271154B2 (en) 2023-07-01
JP2023062064A (ja) 2023-05-02
SA519410729B1 (ar) 2022-07-03
PT3915994T (pt) 2024-02-15
JP7229945B2 (ja) 2023-02-28
JOP20190282A1 (ar) 2019-12-05
DOP2019000305A (es) 2019-01-15
TWI782036B (zh) 2022-11-01
ES2971319T3 (es) 2024-06-04
US20230365580A1 (en) 2023-11-16
IL271154B1 (en) 2023-03-01
WO2018225009A1 (en) 2018-12-13
PL3915994T3 (pl) 2024-05-20
EP3915994A1 (en) 2021-12-01
KR20200013046A (ko) 2020-02-05
US20210347784A1 (en) 2021-11-11
CU20190098A7 (es) 2020-10-20
US12209096B2 (en) 2025-01-28
EP3915994B9 (en) 2024-02-28
AU2018279306C1 (en) 2021-01-14
MX2019014757A (es) 2020-02-12
AU2018279306B2 (en) 2020-07-09
AR113227A1 (es) 2020-02-19
DK3915994T3 (da) 2024-02-19
MY198288A (en) 2023-08-21
CL2019003564A1 (es) 2020-06-19
ZA201907358B (en) 2022-04-28
US11753416B2 (en) 2023-09-12
UY37759A (es) 2019-01-31
IL271154A (en) 2020-01-30
EA201992858A1 (ru) 2020-04-02
EP3915994B1 (en) 2023-11-22
CA3063985A1 (en) 2018-12-13
RU2019144107A (ru) 2021-07-09
RS65161B1 (sr) 2024-02-29
JP2020522550A (ja) 2020-07-30
HUE065194T2 (hu) 2024-05-28
SI3915994T1 (sl) 2024-03-29
LT3915994T (lt) 2024-02-26
US11091499B2 (en) 2021-08-17
ECSP19086712A (es) 2019-12-27

Similar Documents

Publication Publication Date Title
WO2020259679A1 (zh) 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
TWI828712B (zh) 作為trk抑制劑的雜環化合物
US12209096B2 (en) Compounds and compositions for inducing chondrogenesis
TW201623310A (zh) 用於誘發軟骨生成之化合物及組合物
CN110167937A (zh) 作为蛋白质聚集调节剂的二环双-杂芳基衍生物
JP2025530234A (ja) Pi3k阻害剤としてのイソキノロン
EP3891154B1 (en) 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
CN104725363A (zh) 取代的哌嗪化合物及其使用方法和用途
HK40096806A (en) Compounds and compositions for inducing chondrogenesis
RU2773943C2 (ru) Соединения и композиции для индуцирования хондрогенеза
HK40055222B (en) Compounds and compositions for inducing chondrogenesis
HK40055222A (en) Compounds and compositions for inducing chondrogenesis
ES2965684T3 (es) Derivados de 6-hidroxi-8-oxatriciclo[3.2.1.02,4]octano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular
WO2025072673A1 (en) Thiazole derivatives and their use as ire 1 inhibitors
EA040531B1 (ru) Соединения и композиции для индукцирования хондрогенеза

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]